Simon Data hauls in $30M Series C to continue building customer data platform

As businesses use an increasing variety of marketing software solutions, the goal around collecting all of that data is to improve customer experience. Simon Data announced a $30 million Series C round today to help. The round was led by Polaris Partners . Previous investors .406 Ventures and F-Prime Capital also participated. Today’s investment brings […]

Neurobehavioral health company BlackThorn pulls in $76 million from GV to treat mental disorders

There are numerous challenges to finding effective treatments for mental disorders. However, BlackThorn Therapeutics, a neurobehavioral health company using machine learning to create personalized medicine for mental health, is betting its technological approach to finding drugs that work will put it ahead of the competition. Lucky for them, GV and other biotech investors have shown […]

Microbiome testing service uBiome puts its co-founders on administrative leave after FBI raid

The microbiome testing service uBiome has placed its founders and co-chief executives, Jessica Richman and Zac Apte, on administrative leave following an FBI raid on the company’s offices last week. The company’s board of directors have named John Rakow, currently the company’s general counsel, as its interim chairman and chief executive, the company said in […]

Recent departures hint at turmoil at Quartet Health, a mental health startup backed by GV

Backed with nearly $87 million in venture capital funding from GV, Oak HC/FT and F-Prime Capital, Quartet Health was founded in 2014 by Arun Gupta, Steve Shulman and David Wennberg to improve access to behavioral healthcare. Its mission: “enable every person in our society to thrive by building a collaborative behavioral and physical health ecosystem.” Recent […]

While tech waffles on going public, biotech IPOs boom

For people who make investment decisions based on revenues and projected earnings, biotech IPOs are kind of a non-starter. Not only are new market entrants universally unprofitable, most have zero revenue. Going public is mostly a means to raise money for clinical trials, with red ink expected for years to come. That pattern may be […]